U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Controlled absorption diltiazem formulations

Patent 5002776 Issued on March 26, 1991. Estimated Expiration Date: Icon_subject November 18, 2008. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Patent References

Compressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating
Patent #: 4432966
Issued on: 02/21/1984
Inventor: Zeitoun ,   et al.

Pharmaceutical compositions and methods for producing alpha antagonism
Patent #: 4496558
Issued on: 01/29/1985
Inventor: DeMarinis ,   et al.

Pharmaceutical multiple-units formulation
Patent #: 4606909
Issued on: 08/19/1986
Inventor: Bechgaard ,   et al.

Dosage units for controlled release of active material
Patent #: 4666702
Issued on: 05/19/1987
Inventor: Junginger

Sustained release tablets and method of making same Patent #: 4684516
Issued on: 08/04/1987
Inventor: Bhutani

Inventors

Assignee

Application

No. 273192 filed on 11/18/1988

US Classes:

424/497, Containing solid synthetic polymers424/494, Cellulose derivatives424/495Ethyl cellulose

Examiners

Primary: Page, Thurman K.

Attorney, Agent or Firm

International Classes

A61K 009/16
A61K 009/50

Foreign Application Priority Data

1987-11-20 IE

Abstract

A controlled absorption diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane surrounding the core and containing a major proportion of a pharmaceutically acceptable film-forming water insoluble synthetic polymer and optionally a minor proportion of a pharmaceutically acceptable film-forming, water soluble synthetic polymer. The number of layers in the membrane and the ratio of the water soluble to water insoluble polymer, when said water soluble polymer is present, being effective to permit release of diltiazem from the pellet at a rate allowing controlled absorption thereof over not less than a twelve hour period following oral administration. The pellet has a dissolution rate in vitro which when measured in a dissolution apparatus (paddle) according to U.S. Pharmacopoeia XXI in 0.05 M KCl at pH 7.0 results in not more than 35% of the total diltiazem being released after 2 hours of measurement. Not more than 60% of the total diltiazem is released after four hours of measurement and 100% of the diltiazem is released no earlier than after 8 hours of measurement in said apparatus.

PatentsPlus Images
Enhanced PDF formats
loading...
PatentsPlus: add to cart
PatentsPlus: add to cartSearch-enhanced full patent PDF image
$9.95more info
PatentsPlus: add to cart
PatentsPlus: add to cartIntelligent turbocharged patent PDFs with marked up images
$18.95more info
 
Sign InRegister
Username  
Password   
forgot password?